A unique biological in-vivo model to evaluate follicular development during in-vitro maturation treatment S.E. Elizur, W.Y. Son, H. Clarke, D. Morris, Y. Gidoni, E. Demirtas, S.L. Tan Reproductive BioMedicine Online Volume 22, Issue 3, Pages 257-262 (March 2011) DOI: 10.1016/j.rbmo.2010.11.012 Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions
Figure 1 Serum oestradiol concentrations 7–9days after 10,000IU human chorionic gonadotrophin (HCG) injection in 12 women with regular cycles undergoing HCG-primed in-vitro maturation treatment without hormonal luteal support. Reproductive BioMedicine Online 2011 22, 257-262DOI: (10.1016/j.rbmo.2010.11.012) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions
Figure 2 Serum progesterone concentrations 7–9days after 10,000IU human chorionic gonadotrophin (HCG) injection in 13 women with regular cycles undergoing HCG-primed in-vitro maturation treatment without hormonal luteal support. Reproductive BioMedicine Online 2011 22, 257-262DOI: (10.1016/j.rbmo.2010.11.012) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions
Figure 3 Receiver operating characteristic curve of the dominant follicle diameter predicting the formation of a progesterone-producing corpus luteum (>10nmol/l) in response to LH surge 7–9days after human chorionic gonadotrophin administration. Reproductive BioMedicine Online 2011 22, 257-262DOI: (10.1016/j.rbmo.2010.11.012) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions